Key Highlights

  • 0.12 is the consensus EPS estimate for SBC Medical Group (NASDAQ:SBC) ahead of its November 13, 2026 report, compared with basic EPS of 0.10 reported for the second quarter of 2026.
  • 49 million USD is the total Revenue reported for the second quarter of 2026, up 13% from 43 million USD, while Net Income attributable rose 335% to 11 million USD.
  • 20 million USD is the adjusted EBITDA reported for the second quarter of 2026, a 41% margin, and cash and equivalents were 184 million USD per management commentary.
  • 538.92 million USD is the market Capitalization per the screener snapshot, and the report is flagged for before the market opens on November 13, 2026.

What Investors Expect From SBC Medical Group (NASDAQ:SBC) on November 13, 2026

Per the screener snapshot, SBC Medical Group Holdings Incorporated reports third quarter 2026 results on November 13, 2026, before the market opens, with a consensus EPS estimate of 0.12 and a market capitalization of USD 538.92 million. The estimate sits above the second quarter basic EPS of USD 0.10 and the first-half figure of USD 0.21, which was down from USD 0.23 a year earlier. Second quarter revenue was USD 49 million, first-half revenue was USD 92 million versus USD 91 million, and first-half net income was USD 22 million versus USD 24 million.

The Rationale: Last Reported Quarter and Management Outlook for SBC Medical Group (NASDAQ:SBC)

In the quarter ended June 30, 2026, net income attributable was USD 11 million versus USD 2 million, a 22% Margin versus 6%, and adjusted EBITDA was USD 20 million versus USD 15 million. Annualized Return on Equity was 16% versus 4%. The company operated 287 locations, up 34 year on year, with 6.9 million last-twelve-month patient visits, up 10%, and average spend per visit of USD 287, up 9%. Management said the quarter marked a clear reacceleration, attributing it to an expanded points Business and higher AI-enabled service fees. The CEO said fee revisions could add about USD 15 million of annual service fees if realized for a full year. Formal 2026 guidance was not provided.

Valuation, Liquidity and Risks for SBC Medical Group (NASDAQ:SBC)

Cash and cash equivalents were USD 184 million, according to the CEO commentary, against a Market Value of USD 538.92 million per the screener snapshot (calculated cash is about 34% of that value). Debt, Operating Income and dividends were not found in the release. Strategic priorities include multi-brand aesthetic dermatology, a non-aesthetic business as a second growth engine, expansion with OrangeTwist in the US and in ASEAN anchored in Thailand, and entry into the longevity market. Risks include a yen exposure (the release used JPY 158.1 per USD), healthcare regulation, reliance on Franchise and service fees, uneven first-half trends and new-market execution.

Where Things Stand

Where things stand: SBC Medical Group (NASDAQ:SBC) reports with a consensus EPS estimate of 0.12, a market capitalization of USD 538.92 million and USD 184 million of cash. The second quarter showed a rebound, with USD 49 million of revenue, USD 11 million of net income and a 41% adjusted EBITDA margin, but first-half net income of USD 22 million still trailed the USD 24 million of the prior year. Investors will watch whether growth holds, whether fee revisions lift service fees, how new markets develop, and whether margins stay near recent levels. No formal numerical guidance was published. This is information only and not Investment advice.